May 29, 2020 at 8:00 AM EDT

  • Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020
  • Company signed $80 million in private placement financing with biotechnology focused institutional investors
  • New Board Chair, Chief Medical Officer and Chief Financial Officer appointed

BALA CYNWYD, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Chondrial Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the completion of its reverse merger with Zafgen, Inc. (Nasdaq:ZFGN). The combined, publicly traded clinical-stage biotechnology company will operate under the name Larimar Therapeutics, Inc. and its shares will commence trading on the Nasdaq Global Market on May 29, 2020, under the ticker symbol “LRMR.”

View the PDF